Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949425 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04949425: Clinical Trial Phase 1 study, sponsored by AstraZeneca.
NCT04949425 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04949425, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology studies (hereafter referred to as the 'parent studies') who continue to use the therapy
Primary Outcome
Assessment of the safety and tolerability of adavosertib following oral dosing of the capsule formulation in patients with advanced solid tumours
Interventions
- DRUG Adavosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 1 |
Why NCT04949425 stopped before completion
NCT04949425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Adavosertib is the first listed.
NCT04949425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04949425 about?
NCT04949425 is a clinical study titled "A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours". The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology s...
What is the current status of trial NCT04949425?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-09-13. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT04949425?
The interventions under investigation include: Adavosertib (DRUG).
Who is sponsoring clinical trial NCT04949425?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04949425's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI